Ionis Pharmaceuticals
Market Cap
US$8.7b
Last Updated
2021/01/27 23:27 UTC
Data Sources
Company Financials +
Executive Summary
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Ionis Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IONS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: IONS's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
-5.4%
IONS
-4.7%
US Biotechs
-2.7%
US Market
1 Year Return
-2.5%
IONS
39.6%
US Biotechs
21.2%
US Market
Return vs Industry: IONS underperformed the US Biotechs industry which returned 44.4% over the past year.
Return vs Market: IONS underperformed the US Market which returned 24.3% over the past year.
Shareholder returns
| IONS | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.4% | -4.7% | -2.7% |
| 30 Day | 0.4% | 4.0% | 1.8% |
| 90 Day | 26.3% | 22.6% | 16.4% |
| 1 Year | -2.5%-2.5% | 41.9%39.6% | 23.9%21.2% |
| 3 Year | 12.7%12.7% | 21.9%15.3% | 43.7%34.2% |
| 5 Year | 66.8%66.8% | 56.7%44.4% | 124.3%99.2% |
Long-Term Price Volatility Vs. Market
How volatile is Ionis Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?4 weeks ago | Simply Wall St
Ionis Pharmaceuticals (NASDAQ:IONS) Shareholders Booked A 16% Gain In The Last Three Years1 month ago | Simply Wall St
Calculating The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Valuation
Is Ionis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
43.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IONS ($59.19) is trading below our estimate of fair value ($105.32)
Significantly Below Fair Value: IONS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IONS is poor value based on its PE Ratio (114x) compared to the US Biotechs industry average (33.5x).
PE vs Market: IONS is poor value based on its PE Ratio (114x) compared to the US market (21.2x).
Price to Earnings Growth Ratio
PEG Ratio: IONS is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: IONS is overvalued based on its PB Ratio (6x) compared to the US Biotechs industry average (4.5x).
Next Steps
Future Growth
How is Ionis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
60.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IONS's forecast earnings growth (60.3% per year) is above the savings rate (2%).
Earnings vs Market: IONS's earnings (60.3% per year) are forecast to grow faster than the US market (21.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IONS's revenue (13.9% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: IONS's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IONS is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Ionis Pharmaceuticals performed over the past 5 years?
59.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IONS has high quality earnings.
Growing Profit Margin: IONS's current net profit margins (7.8%) are lower than last year (52.3%).
Past Earnings Growth Analysis
Earnings Trend: IONS's earnings have grown significantly by 59% per year over the past 5 years.
Accelerating Growth: IONS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IONS had negative earnings growth (-83.2%) over the past year, making it difficult to compare to the Biotechs industry average (-10.3%).
Return on Equity
High ROE: IONS's Return on Equity (3.6%) is considered low.
Next Steps
Financial Health
How is Ionis Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: IONS's short term assets ($2.5B) exceed its short term liabilities ($244.6M).
Long Term Liabilities: IONS's short term assets ($2.5B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: IONS's debt to equity ratio (49.7%) is considered high.
Reducing Debt: IONS's debt to equity ratio has reduced from 163.6% to 49.7% over the past 5 years.
Debt Coverage: IONS's debt is well covered by operating cash flow (27%).
Interest Coverage: IONS's interest payments on its debt are well covered by EBIT (14.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IONS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IONS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IONS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IONS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IONS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Brett Monia (59 yo)
1
Tenure
US$6,527,963
Compensation
Dr. Brett P. Monia, Ph.D., is a Founder of Ionis Pharmaceuticals, Inc. and has been its Chief Executive Officer since 2020. He is President and Director of Akcea Therapeutics, Inc. since October 12, 2020. ...
CEO Compensation Analysis
Compensation vs Market: Brett's total compensation ($USD6.53M) is about average for companies of similar size in the US market ($USD6.31M).
Compensation vs Earnings: Brett's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 29.92yrs | US$9.60m | 0.43% $ 37.7m | |
| Founder | 1yr | US$6.53m | 0.035% $ 3.0m | |
| Executive VP of Finance & CFO | 8yrs | US$3.48m | 0.031% $ 2.7m | |
| Executive VP of Legal | 8yrs | US$3.46m | 0.023% $ 2.0m | |
| Senior Strategic Advisor & Director | 20.33yrs | US$2.43m | 0.047% $ 4.1m | |
| Executive VP & Chief Development Officer | 12.42yrs | US$3.91m | 0.030% $ 2.6m | |
| Chief Accounting Officer & Senior VP | 0.92yr | no data | no data | |
| Executive VP & Chief Scientific Officer | 1yr | US$958.87k | 0.030% $ 2.7m | |
| Vice President of Investor Relations | 8.5yrs | no data | no data | |
| Vice President of Marketing & Communications | no data | no data | no data | |
| Executive VP and Chief Corporate Development & Commercial Officer | 1yr | no data | no data | |
| Senior Vice President of Human Resources | 0.92yr | no data | no data |
2.0yrs
Average Tenure
60.5yo
Average Age
Experienced Management: IONS's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 29.92yrs | US$9.60m | 0.43% $ 37.7m | |
| Founder | 1yr | US$6.53m | 0.035% $ 3.0m | |
| Senior Strategic Advisor & Director | 20.33yrs | US$2.43m | 0.047% $ 4.1m | |
| Independent Director | 1.58yrs | US$3.23m | 0.0038% $ 333.1k | |
| Independent Director | 15.08yrs | US$1.17m | 0.0099% $ 868.9k | |
| Independent Director | 27yrs | US$1.16m | 0.063% $ 5.5m | |
| Independent Director | 19.83yrs | US$1.15m | 0.024% $ 2.1m | |
| Independent Director | 2.33yrs | US$1.15m | 0.0038% $ 333.1k | |
| Independent Director | 7.58yrs | US$1.15m | 0.014% $ 1.2m | |
| Independent Director | 18.67yrs | US$1.16m | 0.072% $ 6.3m | |
| Independent Director | 6.92yrs | US$1.14m | 0.012% $ 1.1m | |
| Independent Director | 2.33yrs | US$1.13m | 0.0038% $ 333.1k |
11.3yrs
Average Tenure
67.5yo
Average Age
Experienced Board: IONS's board of directors are seasoned and experienced ( 11.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Ionis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ionis Pharmaceuticals, Inc.
- Ticker: IONS
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.742b
- Shares outstanding: 139.82m
- Website: https://www.ionispharma.com
Number of Employees
Location
- Ionis Pharmaceuticals, Inc.
- 2855 Gazelle Court
- Carlsbad
- California
- 92010
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IONS | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 1991 |
| ISI | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1991 |
| IONS | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | May 1991 |
| 0JDI | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1991 |
| IONS * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 1991 |
Biography
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/27 23:27 |
| End of Day Share Price | 2021/01/27 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.